Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CADL vs EVMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CADL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)
CADL Overall Winner
6-Pillar Tally: CADL 3 – 2 EVMN (1 Tie)
Matrix Metrics: CADL 5 – 2 EVMN
As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CADL carries a Unified Composite Score of 46.0/100 (HOLD) at $5.81 (43.5x Forward P/E, 0.0% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CADL vs EVMN
CADL
Head-to-Head Winner
Candel Therapeutics, Inc. Common Stock
$5.81
-6.29% 1D
Market Cap
$486.4M
TTM Revenue
$31,000
Forward P/E
43.5x
Beta / 30D Vol
2.12β · 125% Vol
Unified Composite Score
46.0
HOLD
Tech 33.0
Fund 55.0
Flow 70.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
EVMN
Evommune, Inc.
$7.10
-6.95% 1D
Market Cap
$315.5M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.05β · 118% Vol
Unified Composite Score
30.0
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CADL 3 – 2 EVMN)
1. Valuation Multiples
CADL
Forward P/E
43.5x
N/M
Trailing P/E
43.5x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
CADL
Revenue Growth (YoY)
+0.0%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31,000
N/A
Market Cap
$486.4M
$315.5M
3. Profitability & Quality
EVMN
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-93.7%
-69.5%
4. Balance Sheet & Cash Flow
CADL
Cash Generation (TTM)
-$57M
-$75M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$152M Net Cash
$52M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EVMN
Options Structure Phase
BREAKDOWN
SURGE
Current IV / %ile
115.4% (24th %ile)
209.0% (53rd %ile)
Put/Call OI Skew
0.50x (Call-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CADL (5) vs EVMN (2)| Institutional Metric | CADL | EVMN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $486.4M | $315.5M | CADL | |
| Trailing P/E Ratio | 43.5x | N/M | CADL | |
| Forward P/E Ratio | 43.5x | N/M | CADL | |
| Revenue Growth (YoY) | +0.0% | +0.0% | Tie | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -93.7% | -69.5% | EVMN | |
| 52-Week Range Position | 15% ($4–$14) | 8% ($5–$33) | CADL | |
| Beta / 30D Volatility | 2.12β · 125% Vol | 1.05β · 118% Vol | EVMN | |
| Unified Institutional Score | 46.0 / 100 (HOLD) | 30.0 / 100 (SELL) | CADL | |
| Trailing 12M Revenue (USD) | $31,000 | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$57M ($152M Net Cash) | -$75M ($52M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EVMN +66.39 pp
3M Horizon
EVMN +1.71 pp
6M Horizon
CADL +41.11 pp
1Y Horizon
CADL +87.06 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CADL Revenue | EVMN Revenue | CADL Op. Margin | EVMN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -11048.0% | N/A | CADL |
| FY2021 | $0M | N/A | -20580.8% | N/A | CADL |
| FY2022 | $0M | N/A | -27777.6% | N/A | CADL |
| FY2024 | N/A | $10M | N/A | -1000.2% | EVMN |
| FY2025 | N/A | $10M | N/A | -623.6% | EVMN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CADL
BREAKDOWN
Current IV
115.4%
IV Percentile
24th %ile
Put/Call OI Skew
0.50x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact CADL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EVMN
SURGE
Current IV
209.0%
IV Percentile
53rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CADL Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EVMN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CADL vs EVMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CADL carries a Unified Composite Score of 46.0/100 (HOLD) at $5.81 (43.5x Forward P/E, 0.0% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CADL leads the Growth & Scale pillar: CADL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $31,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 5-period historical trajectory (FY2020 to FY2025), CADL cumulative revenue shifted N/A while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, CADL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.
CADL screens cheaper on headline valuation multiples. CADL trades at 43.5x Forward P/E, 43.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CADL (-93.7% ROE) versus EVMN (-69.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CADL carries 115.4% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.12β · 125% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EVMN vs CADL · Reverse Pair
CADL vs IMRX
· Sector Peer
CADL vs JANX
· Sector Peer
CADL vs CING
· Sector Peer
EVMN vs MPLT
· Sector Peer
EVMN vs ALMS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem